Arsenic Trioxide
- Atc Codes:L01XX27
- CAS Codes:1327-53-3
- PHARMGKB ID:1327-53-3
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Trisenox; Belgium: Trisenox; Bulgaria: Trisenox; Cyprus: Trisenox; Czech Republic: Trisenox; Estonia: Trisenox; France: Trisenox; Germany: Trisenox; Greece: Trisenox; Hungary: Trisenox; Ireland: Trisenox; Italy: Trisenox; Latvia: Trisenox; Lithuania: Trisenox; Luxembourg: Trisenox; Malta: Trisenox; Netherlands: Trisenox; Poland: Trisenox; Portugal: Trisenox; Romania: Trisenox; Slovakia: Trisenox; Slovenia: Trisenox; Spain: Trisenox; Sweden: Trisenox; UK: Trisenox.
North America
USA: Trisenox.
Asia
Japan: Trisenox.
Drug combinations
Chemistry
Arsenic Trioxide: As~2~O~3~. Mw: 197.84. Diarsenic trioxide. CAS-1327-53-3 (2001).
Pharmacologic Category
Other Antineoplastic Agents. (ATC-Code: L01XX27).
Mechanism of action
Causes in vitro morphological changes and DNA fragmentation to NB4 human promyelocytic leukemia cells. Damages/degrades the fusion protein PML-RAR-α.
Therapeutic use
Induction of remission and consolidation in relapsed or refractory acute promyelocytic leukemia.
Pregnancy and lactiation implications
Crosses the human placenta. Pregnancy should be avoided. Not recommended during lactation.
Unlabeled use
Treatment of myelodysplastic syndrome, multiple myeloma.
Contraindications
Hypersensitivity to arsenic or any component of the formulation.
Warnings and precautions
Hazardous agent. May cause retinoic-acid-acute promyelocytic leukemia syndrome or APL differentiation syndrome (dyspnea, fever, weight gain, pulmonary infiltrates, and pleural or pericardial effusions) in acute promyelocytic leukemia. Risk of hyperleukocytosis. May prolong the QT interval. May lead to torsade de pointes or complete AV block. May produce electrolyte imbalances. Use with caution in renal impairment (renal excretion).